Drugs.com - Clinical Trials

Zentalis Pharmaceuticals Presents Updated Azenosertib Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer...

Mar 18, 2025 - 01:11
 0
Zentalis Pharmaceuticals Presents Updated Azenosertib Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer...
Read More

Tags:

Previous Article

Longévité : l'industrie cosmétique doit repenser son rapport à l'âge

Next Article

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Produ...

Related Posts

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Eledon Pharmaceuticals Announces Use of Tegoprubart as ...

Feb 9, 2025  0

Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease

Genentech’s Phase IIb Study of Prasinezumab Missed Prim...

Feb 9, 2025  0

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical...

Mar 9, 2025  0